|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostalimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
|
|
W25-046-2
|
|
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostalimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
|
|
Dr. Upendra Hegde
|
|
The purpose of this study is to find out if an experimental drug, called dostarlimab, via 11 administrations starting shortly after chemoradiotherapy (CRT) has finished, can delay or reduce the risk of cancer returning when compared to placebo given over the same time period following CRT.
|
Cancer - Head and Neck, Including Mouth
|
|
|
Check with study contact
|
|
Kristen Grandonico. Telephone: 860-679-6580. Email: grandonico@uchc.edu
|
|
Enrolling/recruiting.
|
|
|